• vTv Therapeutics filed a prospectus supplement to raise the number of shares of Class A common stock that can be sold under its at-the-market sales program to the program’s full authorized amount.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. vTv Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-221971), on May 13, 2026, and is solely responsible for the information contained therein.